Limbic versus cognitive target for deep brain stimulation in treatment-resistant depression: Accumbens more promising than caudate  by Millet, Bruno et al.
European Neuropsychopharmacology (2014) 24, 1229–1239http://dx.doi.org/1
0924-977X/& 2014 E
☆Bruno Millet, Ne
Bertrand Devaux, Jé
Vérin, Sophie Drapie
Sthym network.www.elsevier.com/locate/euroneuroLimbic versus cognitive target for deep brain
stimulation in treatment-resistant
depression: Accumbens more promising
than caudate$
Bruno Milleta,b, Nematollah Jaafaric, Mircea Polosand,
Nicolas Baupe, Bruno Giordanaf, Claire Haegeleng,
Stephan Chabardesh, Denys Fontainei, Bertrand Devauxj,
Jérome Yelnikk, Philippe Fossatil, Bruno Aouizeratem,
Marie Odile Krebse, Gabriel Roberta,b, Thérèse Jayn,
Philippe Cornuo, Marc Vérinb,p, Sophie Drapierq,
Dominique Drapiera,b, Paul Sauleaub,r, Julie Perons,
Florence Le Jeuneb,t, Florian Naudetb,u,n, Jean Michel ReymannuaUniversity Department of Adult Psychiatry, Guillaume Régnier Hospital, Rennes, France
bBehavior and Basal Ganglia Unit (EA-4712), University of Rennes 1, Rennes, France
cIntersector Clinical Psychiatric Research Unit (INSERM U 1084), Psychobiology of Compulsive Disorders
Team, Experimental and Clinical Neurosciences Laboratory, Henri Laborit Hospital, University of Poitiers,
France
dD Villars Ward (Adult Psychiatry), Department of Psychiatry and Neurology, North Hospital, University
Hospital, Grenoble, France
eAdolescent and Young Adult Assessment Center, Sainte-Anne Hospital, Paris, France
fPsychiatry and Medical Psychology Clinic, University Department of Clinical Neuroscience, Pasteur
University Hospital, Nice, France
gDepartment of Neurosurgery, Pontchaillou University Hospital, Rennes, France
hDepartment of Neurosurgery, University Hospital, Grenoble, France
iDepartment of Neurosurgery, Pasteur University Hospital, Nice, France
jDepartment of Neurosurgery, Sainte-Anne Hospital, Paris, France
kCRICM UPMC/INSERM UMR S 975, CNRS UMR 7225, La Salpêtrière Hospital, Paris, France
lDepartment of Psychiatry, Pitié-Salpêtrière Hospital, Paris, France
mUniversity Department of Adult Psychiatry, Charles Perrens Hospital, Bordeaux, France
nInserm U894, Center for Psychiatry and Neuroscience, Paris Descartes University, Paris, France
oDepartment of Neurosurgery, Pitié-Salpêtrière Hospital, Paris, France0.1016/j.euroneuro.2014.05.006
lsevier B.V. and ECNP.
mat Jaafari, Mircea Polosan, Nicolas Baup, Bruno Giordana, Claire Haegelen, Stephan Chabardès, Denys Fontaine,
rome Yelnik, Philippe Fossati, Bruno Aouizerate, Marie-Odile Krebs, Gabriel Robert, Thérèse Jay, Philippe Cornu, Marc
r, Dominique Drapier, Paul Sauleau, Julie Péron, Florence Le Jeune, Florian Naudet and Jean Michel Reymann for the
Open access under CC BY-NC-ND license.
B. Millet et al.1230pDepartment of Neurology, Pontchaillou University Hosptial, Rennes, France
qDepartment of Neurology, Pontchaillou University Hospital, Rennes, France
rFunctional Neurological Exploration Unit, Pontchaillou University Hospital, Rennes, France
sSwiss Center for Affective Sciences, University of Geneva, Geneva, Switzerland
tDepartment of Nuclear Medicine, Eugène Marquis Center, Rennes, France
uClinical Investigation Center (INSERM 0203), Department of Pharmacology, Pontchaillou University
Hospital, Rennes, FranceReceived 29 October 2013; received in revised form 10 March 2014; accepted 9 May 2014KEYWORDS
Deep brain stimula-
tion;
Accumbens;
Caudate;
Treatment-resistant
depression;
Therapeutic trialnCorresponding author at: Pôle Hosp
ment et noyaux gris centraux”, 35703
E-mail address: ﬂoriannaudet@gmaAbstract
High-frequency deep brain stimulation (DBS) represents a major stake for treatment for
treatment-resistant depression (TRD). We describe a preliminary trial of DBS of two potential
brain targets in chronic TRD: the nucleus accumbens (Acb) and, in the event of failure, the
caudate nucleus. Patients were followed for 6 months before surgery (M0). From M1 to M5, they
underwent stimulation of the Acb target. PET scans allowed us to track metabolic modiﬁcations
resulting from this stimulation. The caudate target of nonresponders was stimulated between
M5 and M9. Patients then entered an extension phase, in which it was possible to adapt
stimulation parameters and treatments. Six patients were included and four were operated on.
At M5, none of the patients were either responders or remitters, but we did observe a decrease
in Hamilton Depression Rating Scale (HDRS) scores. Three patients were switched to caudate
stimulation, but no improvement was observed. During the extension phase, the Acb target was
stimulated for all patients, three of whom exhibited a signiﬁcant response. A decrease in
glucose metabolism was observed after Acb stimulation, in the posterior cingulate gyrus, left
frontal lobe, superior and medial gyrus, and bilateral cerebellum. An increase in metabolism
was observed in the bilateral frontal lobe (superior gyrus), left frontal lobe (medial gyrus), and
right limbic lobe (anterior cingulate gyrus). The results of this trial suggest that Acb is a more
promising target than the caudate. NCT01569711.
& 2014 Elsevier B.V. and ECNP. All rights reserved.1. Introduction
Major depressive disorder (MDD) is one of the leading causes
of handicap worldwide (Lopez et al., 2006). It contributes to
an increase in mortality (Murphy et al., 1987), through
suicide and cardiovascular disease (Musselman et al., 1998).
Its consequences include recurrences, with a ﬁve-year rate
of 80%, and chronicity for 20% of patients (Eaton et al.,
2008; Keller, 2003). 30% of depression cases prove resistant
to antidepressant drugs (Fava, 2003). The medical histories
of these patients are marked by multiple hospitalizations,
and by multiple trials of ultimately ineffectual and there-
fore discouraging treatments. This so-called chronic,
treatment-resistant depression (TRD) is a major public-
health issue, as well as a pathophysiological conundrum.
Several data suggest that dysfunctional brain circuits are
implicated, and that high-frequency deep brain stimulation
(DBS) could represent an adjustable and reversible method
of modulating these brain areas, just as it does for
neurological disorders (Houeto et al., 2005; Houeto et al.,italo-Universitaire de Psychiatrie
Rennes Cedex 7, France. Tel.: +
il.com (F. Naudet).2007) and obsessive-compulsive disorder (OCD) (Mallet
et al., 2008).
In TRD, a number of case reports have been published,
describing a range of different targets, including the lateral
habenula (Sartorius et al., 2010), inferior thalamic pedoncle
(Jimenez et al., 2005), and the medial forebrain bundle
(Coenen et al., 2011). Using larger samples, Mayberg and
Lozano reported striking results over the short (Lozano
et al., 2012,2008) and longer-term (Holtzheimer et al.,
2012) effects of DBS targeting the subgenual cingulate
cortex. Their results have been conﬁrmed by Puigdemont
et al. (2012). Other teams (Bewernick et al., 2010;
Bewernick et al., 2012; Malone et al., 2009; Schlaepfer
et al., 2008) have also obtained promising results with brain
targets corresponding to the ventral part of the striatum,
including the ventral caudate and nucleus accumbens (Acb).
There are currently many arguments in favor of using Acb
as the main target. This structure lies at the center of a
circuit involved in depression that is connected to the
ventral tegmental area, amygdala, hippocampus,Adulte, Centre hospitalier Guillaume Régnier, EA 4712 “Comporte-
33 2 99 33 39 37; fax: +33 2 99 33 39 72.
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tories of the caudate nucleus and globus pallidus. It also
indirectly projects to cortical regions including the subgen-
ual cingulate in Brodmann area (BA) 25 (Cg25) and the
medial prefrontal cortex, ventral pallidum, thalamus, and
amygdala (Dinieri et al., 2009; Mogenson et al., 1983). Acb
is a critical reward and pleasure center, and thus constitutes
a key target in the treatment of depression, given that
anhedonia is one of the disorder's key deﬁning symptoms
(Schlaepfer et al., 2008). Meta-analyses of neurosurgical
procedures carried out to treat TRD have found that nearly
80% of patients beneﬁt when the lesions affect Acb and the
ventral part of the head of the caudate (Greenberg et al.,
2003; Hodgkiss et al., 1995). Several studies have demon-
strated the effectiveness of targeting the ventral striatum
in depressive symptoms, especially when it is stimulated
close to Acb (Aouizerate et al., 2005a; Aouizerate et al.,
2005b; Bewernick et al., 2010,2012; Malone et al., 2009;
Schlaepfer et al., 2008).
In addition, within our consortium, Yelnik et al. (2007)
and Bardinet et al. (2009) have developed a speciﬁc atlas
distinguishing between three territtories (sensorimotor,
associative and limbic) of the basal ganglia related to
cortical areas within the cortico-subcortical circuits (Bar-
Gad and Bergman, 2001; Parent and Hazrati, 1995a, 1995a).
If we assume that DBS works by modulating the effects of
the cortico-subcortical loops on a pathological dysfunction,
as it is the case for subthalamic DBS in OCD (Le Jeune et al.,
2010), when attempting to improve TRD, it seems relevant
to target limbic areas in the basal ganglia, rather than
cognitive or sensorimotor ones. For this reason, the French
STHYM network decided to compare a limbic target (i.e.,
Acb) with a cognitive one (i.e., caudate), using an electrode
capable of stimulating both nuclei.
2. Experimental procedures
The protocol was approved by the local ethics committee in Angers,
France (no. 2008/16). All patients gave their written informed
consent to take part. The study was registered with the clinical–
trials.gov database (NCT01569711).
2.1. Patients
Patients with chronic and recurrent TRD were recruited in 10
French centers. Inclusion criteria were 1/age between 30 and 60
years, 2/ DSM-IV-TR criteria for MDD, and 3/ episode duration42
years.
Treatment resistance had to meet Thase and Rush Stage V (Thase
and Rush, 1997). Furthermore, patients simultaneously had to have
a 17-item Hamilton Depressive Rating Scale (HDRS) total score421,
a Global Assessment of Functioning (GAF) scoreo50, and a Clinical
Global Impression (CGI) score Z4, despite the use of all the
following strategies: 1/ monotherapies: two SSRIs, one SNRI, one
tricyclic; 2/ the association of one antidepressant and one of the
following treatments: lithium, thyroid hormone, buspirone, pindo-
lol; 3/ an irreversible MAOI: iproniazid; 4/ the association of two
antipsychotics, with at least one second-generation antipsychotic;
5/ the association of two antidepressants; 5/ electroconvulsive
therapy; 6/ structured psychotherapy. The severity of the MDD had
to be constant before surgery.
Exclusion criteria were 1/ serious and unstable medical condi-
tion; 2/ cognitive deterioration; 3/ abnormal brain MRI;4/ contraindication for MRI; 5/ Axis 1 disorder other than MDD
(except for generalized anxiety disorder, social phobia, and panic
disorder); 6/ a substance use disorder (with the exception of
nicotine); 7/ suicide risk in the previous month; 8/ psychotic
features or a history of psychotic features; 9/ personality disorders
according to DSM-IV-TR Cluster A or B; 10/ involuntary commitment,
guardianship or trusteeship; and 11/ woman of childbearing age
without effective contraception.2.2. Preoperative imaging and surgical procedure
Preoperative imaging consisted of an MRI under stereotactic condi-
tions (Bejjani et al., 2000), that is, allowing the stereotactic
coordinates to be determined. The AC-PC line running between
the anterior and posterior commissures was used as a reference,
together with the vertical plane through AC-PC in the middle of V3.
In order to check that there was no vascular disorder adjacent to
the stereotactic target, a vascular MRI was also performed. The
location of the Acb target was agreed upon by the neurosurgeons
and the neuroanatomist, who was in charge of deﬁning the target's
coordinates according to its functional characteristics. These
coordinates were identiﬁed using a deformable 3D atlas that
distinguished among the motor, associative and limbic subdivisions
of the basal ganglia, and which was adapted to the brain geometry
of each patient (Bardinet et al., 2009; Yelnik et al., 2007). An
example of this targeting is shown in Figure. 1 for a patient with an
AC-PC distance of 26 mm and a V3 width of 6 mm. The electrode for
stimulation was placed in the Acb in a frontal plane 5.5 mm in front
of AC, with a laterality of 9 mm and a depth of 6.5 mm below AC-
PC. The trajectory was precisely determined by the neurosurgeon
according to the structure of local blood vessels, taking particular
care to avoid the anterior communicant artery and its branches.
The second target, the caudate nucleus, was located in a more
rostral, dorsal and lateral position than Acb (14 mm, 12.5 mm and
14 mm, in the case of Figure. 1). For each patient, the trajectory
was optimized (in order to pass in the frontal plane) between the
lateral ventricle medially and the internal capsule laterally. In the
sagittal plane, an oblique trajectory was adopted, in order to cross
the limbic and associative areas of the caudate nucleus, but avoid
its sensorimotor territory. In order to retain the ability to stimulate
the two different targets (Acb and caudate nucleus) deﬁned by the
protocol (Figure. 1) along the same trajectory, we chose to use the
3891 Medtronic Pisces Z-Quads lead which is longer than the 3389
lead and in which the four electrodes each measure 3 mm long and
are spaced 4 mm apart (i.e. 7 mm from one center to the next).2.3. Study design
We designed a pilot multicenter prospective, noncomparative, and
open trial. All patients were followed for six months before surgery
(between M-6 and D-7), to verify the stability of their illness.
Surgery was performed at M0. The implanted patients were not
stimulated for the ﬁrst month. From M1 to M5, Acb target was
stimulated. Nonresponders at M5 underwent stimulation of the
caudate target until M9. After these two periods, patients entered a
six-month extension phase (up to M15), in which it was possible to
adapt stimulation parameters and associated treatments.2.4. Initiation of stimulation
The stimulation frequency was set at 130 Hz and the impulse
duration at 60 ms according each investigator. The initial voltage
was 4 V. This level of stimulation was maintained from M1 to M9, but
could subsequently be increased up to 8 V during the extension
phase, keeping the same frequency and width pulse as before.
Target 
Accumbens
CACP = 26 mm
V3 width= 6 mm
ML 9 mm
DV 6.5 mm under CA
AP 5.5 mm from CA
Target 
Associative  caudate
CACP = 26 mm
V3 width = 6 mm
ML 14 mm
DV 12.5 mm under CA
AP 14 mm from CA
Figure. 1 Electrode placement (nucleus accumbens and associative territory of the caudate) after readjustment of the Yelnik &
Bardinet atlas (Yelnik et al, 2007) on the MRI of each patient. The 3D cursor shows the exact position of each target in the three
anatomical planes (transverse, sagittal, and coronal). The mediolateral (ML), dorsoventral (DV) and anteroposterior (AP) coordinates
in the coordinate KABP were also calculated for each patient.
B. Millet et al.12322.5. Outcomes
The primary outcome measure for the study was the clinical
response, assessed after four months of DBS (M5). We adopted
the most widely used response criterion (50% decrease in the HDRS
score). Remission, as deﬁned by an HDRS score r7 after four
months of DBS was a secondary outcome. The other secondary
outcomes assessed during follow-up visits were duration of remis-
sion, depression severity, as measured on the HDRS, the overall
score on the Hamilton Anxiety Rating Scale (HARS) r10, a rating of
1 (very much improved) or 2 (strongly improved) for Item 2 of the
CGI, a score Z60 on the GAF, and increased scores on the Social
Adjustment Scale Self-Report (SAS-SR) and Beck Depression
Inventory (BDI).
The effect of DBS of the caudate nucleus in the event of a
nonresponse at M5 was assessed at M9 using the same scales. During
the extension phase, depression severity was assessed using HDRS.
Individual data are set out in the tables, and summarized numeri-
cally, with the median (range) for quantitative outcomes and the
number (percentage) for qualitative outcomes.2.6. Tolerance and side effects
Tolerance was assessed at each follow-up visit after surgery.
Patients were offered close supervision (telephone contacts and
consultations on request) if they experienced severe side effects.
As DBS of the basal ganglia in Parkinson's disease is known to be
associated with weight gain (WG), and because Acb has been
demonstrated to play a key role in different behaviors, including
eating and sexuality (Baldo and Kelley, 2007; Kelley et al., 2005),
we speciﬁcally monitored these two behaviors. Eating behavior was
assessed via a multidimensional approach that encompassed anthro-
pometric measures (weight, expressed as body mass index (BMI),
hip and abdomen circumferences), hormone levels and daily energyintake (DEI). The latter was assessed via structured dietary ques-
tionnaires administered by a dietician, and self-reported food
consumption over a seven-day period. Food habits, feelings and
thoughts about food, and eating disturbances were assessed on the
Questionnaire of Eating and Weight Pattern Revised (QEWP-R)
(Spitzer et al., 1993), the Eating Attitudes Test-26 (EAT-26)
(Garner et al., 1982), a questionnaire on thoughts and feelings
about food (Rigaud, 2005), and the Food Craving Questionnaire
(Guy-Grand, 1997). The International Erectile Function scale was
used to explore sexual behavior.
A comprehensive battery of neuropsychological tests was also
administered at D-7, M1, M5, and M9, to explore the possible
cognitive toxicity of DBS. This battery included the Mattis scale
(Mattis, 1988) for general cognitive efﬁciency, and a series of tests
assessing memory abilities: the Hopkins test (Rieu et al., 2006) for
verbal episodic memory, and forward (visuospatial) and backward
(auditory-verbal) digit span tests for working memory. Patients also
underwent a series of tests assessing frontal executive functions:
the Trail Making Test (Reitan, 1958), the Categorical and Literal
Fluency Test (Cardebat et al., 1990), the Action Verbs ﬂuency task
(Woods et al., 2005), and the Stroop Test (Stroop, 1935). Finally,
visuospatial abilities were measured by the copying of the Rey
complex ﬁgure (Rey, 1942).2.7. Brain imaging
In order to correlate the effects of stimulation with changes in brain
metabolism, the patients underwent two [18F]FDG PET scans before
and after Acb stimulation. The data, acquired on different PET
cameras, were analyzed using statistical parametric mapping soft-
ware (SPM2; Wellcome Department of Cognitive Neurology, London)
written in Matlab version 7 (MathWorks). This analysis, using an
isotropic smoothing 12-mm full-width at half-maximum Gaussian
kernel ﬁlter to compensate for interindividual anatomical
1233Limbic vs cognitive target for DBS in TRDvariability and render the imaging data more normally distributed,
allowed us to overcome technical differences in machines. Sig-
niﬁcant modiﬁcations in the brain metabolism of the four patients
were pinpointed by comparing their pre- and post-surgery 18FDG
PET scans. We used the “single subject, conditions and covariates”
routine. We studied different thresholds to ﬁnd regions affected by
the stimulation in this very small sample. Clusters of at least 10
contiguous voxels, with a threshold p Value of 0.05, were identiﬁed.
3. Results
3.1. Preoperative period: recruitment and baseline
data
Due to the stringent inclusion criteria and the high number of potential
candidates who responded to Stage-IV or V treatments for TRD (Thase
and Rush, 1997), only six patients were recruited between 12/04/2008
and 03/09/11. Two of these patients were excluded before surgery,
the ﬁrst because a cancer was diagnosed, the second because he
remitted during the six-month preoperative period.
3.2. Deep brain stimulation
Four patients were operated on in the neurosurgery departments of
university hospitals in Rennes, Paris (Sainte Anne), Grenoble and
Nice, in accordance with the usual stereotactic surgical procedure.
The two electrodes were implanted during the same operation
under local anesthesia or intermittent sedation. The neurologist
and psychiatrist attended each perioperative procedure, as did the
study coordinator. Table 1 presents the baseline data.
In the four patients who underwent surgery, the electrodes were
implanted as per the preoperative calculations, that is, with
Contact 0 (ventral) located in Acb, Contact 1 in the limbic caudate
nucleus and Contacts 2 and 3 (dorsal) in the associative caudate.3.3. Postoperative period
3.3.1. Nine-month follow-up
In accordance with the study design, Acb was the initial stimulation
target (Contact 0 on both sides).
None of the patients were responders (primary outcome) or
remitters at the M5 time point, although we did observe a ﬂuctuant
decrease in the HDRS score in three patients during this period
(maxima of 28%, 64% and 93%). Furthermore, none of the
patients achieved an overall score on the HARS r10 (e-Table 1) or
reached a GAF score Z60 during the nine-month postoperative
follow-up. The remission duration criterion was not applicable in
the year of follow-up.
Nevertheless, an improvement was observed in two patients
(Patients 1 and 4), who had remained stable throughout the
preoperative period, and whose mood improved with Acb stimula-
tion (see Figure. 2). These two patients rated Item 2 of the CGI
either 1 (very much improved) or 2 (strongly improved) at various
times during the year of postoperative follow-up, although these
changes ﬂuctuated.
Even though Patient 4 did not strictly meet response criteria at
M5, his clinical improvement led us to continue Acb stimulation.
The other three patients, who were switched to the caudate
nucleus (Patient 1: Contact 2 on left side, Contact 3 on right side;
Patients 2 and 3: Contact 3 on both sides), showed no such
improvement (maximum decrease in the HDRS score of 29%, 16%
and 20%; Figure. 2). Concerning social functioning, scores on the
SAS-SR did not noticeably change during the nine-month post-
operative follow-up (e-Table 1).
Table 1 presents the time course of the secondary outcomes.3.3.2. Extension phase of the study
During the extension phase, all patients underwent Acb stimulation:
Patient 1: the same contact 0 was used. Voltage was increased at
6 V (M9) then 8 V (M12); aripiprazole was added at M11; those
changes allowed for a stable improvement, eventually reaching the
response threshold.
Patient 2: Contact 0 and contact 1 alone or simultaneously were
used with a voltage ranged from 4 to 8 V. No signiﬁcant
improvement was observed.
Patient 3: the same contact was used. Stimulation was increased
to 5 V (M9) and the patient showed a dramatic improvement,
reaching remission at M12 without any concomitant pharmaco-
logical treatment.
Patient 4: the same contact was used. Despite voltage changes
between 5 and 7 V, he experienced the same mood ﬂuctuations
that he had done during the 9-months follow-up, frequently
reaching the response threshold.
3.4. Tolerance and side effects
3.4.1. Safety
Table 2 lists all the adverse events recorded during the study. One
patient made a suicide attempt and presented suicidal thoughts.
3.4.2. Effect on eating and sexual behaviors
Full data were available for three patients. At baseline (M0),
Patient 1 had a BMI of 26.8, a balanced diet, and no eating
disturbances, cravings or abnormal thoughts about food. After
surgery, his diet and habits remained unchanged, he did not have
any abnormal thoughts or eating behaviors, and the different
questionnaires did not reveal any changes. Compared with the
preoperative values, changes in BMI, anthropometric measures, DEI
and most hormone levels were within +/5%. The exceptions were
prolactin, which was found to have increased by 182% at M1 and by
264% at M9, leptin 161% increase at M9), and cortisol (161% increase
at M9). The levels of prolactin and leptin remained within the
normal range, but cortisol slightly exceeded the normal value
(261 ng/ml versus 250 ng/ml). No change in sexual behavior was
reported. Patient 2 had a high BMI of 30.1 at baseline and presented
marked food craving, especially at night and for carbohydrates. This
explained his abnormal score of 29 on the EAT-26. His DEI remained
normal because he did not eat breakfast. Prolactin was at the upper
normal limit (370 mU/ml, No380) and ACTH was slightly on the high
side (62 pg/ml, No52 pg/ml). In the ﬁrst few months after surgery,
both prolactin and ACTH decreased by 60%. Craving had decreased
in both intensity and frequency by M5, at which point the patient
stopped restricting his food intake. As a consequence, his DEI
underwent moderate increases of 8% and 12% at M5 and M9, but
his BMI remained unchanged. The EAT-26 score had dropped to 13 by
M5. Thoughts and feelings about food tended to be more positive,
with greater interest in its gustatory qualities. Excessive food
intake was observed at M0 and an increased appetite for sweets
at M11. These two manifestations were recorded as two adverse
events. A substantial increase in sexual desire (in term of frequency
and intensity) was reported at M1 (as an adverse event) and M5.
Patient 4 intentionally restricted his food consumption at baseline,
adopting a low-calorie diet, but exhibited daily compulsive food
consumption in the afternoon. Craving decreased over the ﬁrst few
months after surgery, but then increased from M4 onwards. He
reported a highly conﬂicting position regarding food, with intense
bouts of anxiety followed by compulsive food consumption, espe-
cially of carbohydrates. These bouts occurred daily, both in the
night and the afternoon, and were followed by guilt-laden feelings
toward eating and negative thoughts about food. His overall DEI had
increased by 82% and his BMI by 7% at M9 (from 28.5 before surgery
to 29.8). His hormone levels remained normal and unchanged
Table 1 Characteristics at baseline and efﬁcacy of DBS (individual data are reported at each time point). The measures are
summarized numerically, with the median (range) for quantitative data and the number (%) for qualitative data.
Patient 1 Patient 2 Patient 3 Patient 4 Group
1/ AT BASELINE
Sex M M F M 1 F/3 M
Current age 57 59 38 54 55.5(38, 59)
Current episode (years) 3.3 3.3 8.0 2.7 3.3(2.7, 8)
Personality disorder Depressive Depressive None None 2(50 %)
2/ DURING FOLLOW-UP
HDRS-17
M-6 24 31 22 21 22.5(21–31)
M-3 22 29 24 27 25.5(22–29)
D-7 25 29 24 27 26(24–29)
M1 22 24 25 26 24.5(22–26)
M2 10 22 25 22 23.5(10–25)
M3 9 24 23 2 16(2–24)
M4 10 30 23 7 16.5(7–30)
M5 24 24 25 25 24.5(24–25)
M6 22 20 22 14 21(14–22)
M7 25 22 23 3 22.5(25–3)
M8 22 24 20 18 21(18–24)
M9 17 24 26 21 22.5(17–26)
M12 11 24 4 9 10(4–24)
M15 8 27 3 14 11(3–27)
CGI
M-6 7 6 6 7 6.5(6, 7)
M-3 6 6 6 7 6(6, 7)
D-7 6 5 6 7 6(5, 7)
M1 6 5 6 6 6(5, 6)
M2 5 5 6 7 5.5(5, 6)
M3 3 5 6 1 4(1, 6)
M4 5 6 6 2 5.5(2, 6)
M5 6 6 6 7 6(6, 7)
M6 6 5 6 5 5.5(5, 6)
M7 6 5 6 1 3(1, 6)
M8 5 5 6 5 5(5, 6)
M9 6 5 6 6 6(5, 6)
BDI
D-7 16 20 27 21 20.5(16, 27)
M1 17 20 30 15 18.5(15, 30)
M5 16 22 30 19 20.5(16, 30)
M9 20 16 27 22 21(16, 27)
GAF
M-6 42 31 22 30 30.5(22, 42)
M-3 35 33 27 31 32(27, 35)
D-7 31 36 23 31 31(23, 36)
M1 35 35 25 31 33(25, 35)
M5 31 31 27 31 29(27, 31)
M9 45 38 23 50 41.5(23, 50)
HDRS-17: Hamilton Depression Rating Scale 17 items.
CGI: Clinical Global Impression.
BDI: Beck Depression Inventory.
GAF: Global Assessment of Functioning.
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1235Limbic vs cognitive target for DBS in TRDthroughout the follow-up period. An increase in his sexual life was
only reported at M1. None of these changes led to an adverse event
declaration.3.4.3. Neuropsychological testing
We did not observe any difference in any of the neuropsychological
scores, especially not between D-7 and M5 (see Group column, e-
Table 2). The only exception to this qualitative observation was the
interference score of the Stroop test between D-7 and M5, pointing
to an increase in inhibition difﬁculties.0
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Figure. 2 2a) Stimulation parameters and 2b) change in HDRS-17
Preoperative period and ﬁrst month with stimulator turned off
Spontaneous interruption of stimulation: stimulation was reactivate3.5. PET measures of regional blood ﬂow at baseline
and after surgery
3.5.1. Brain metabolism
SPM analyses of postoperative (M5) and preoperative scans revealed
several areas of metabolic modiﬁcation in both hemispheres.
Decreased metabolism after stimulation was observed in the
posterior cingulate gyrus (BA 23 and 31) of the right limbic lobe,
the superior (BA 6) and medial gyrus (BA 8) of the left frontal lobe,
and the bilateral cerebellum. Increased metabolism after stimula-
tion was observed in the superior gyrus (BA 9) of the bilateral0
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from baseline: individual data shown. Red line: M0 (surgery)
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Table 2 Safety of DBS, adverse events (AE) recorded over 15 months. The patient columns present the number of AEs
(timeframe) per patient. The Group column presents the number of patients (percentage).
ADVERSE EVENTS Patient 1 Patient 2 Patient 3 Patient 4 Group Patients (%)
Suicide attempt 1 (M9) . . . 1(25%)
Suicidal thoughts 1(M10) . . . 1(25%)
Worsening mood/anxiety 1(M5) 1(M15) . . 2(50%)
Worsening sleep . 2(M1 and M6) . . 1(25%)
Memory problems . 1(M3) . . 1(25%)
Excessive food intake . 1(M0) . . 1(25%)
Increased appetite for sweets . 1(M11) . . 1(25%)
Slightly increased libido . 1(M1) . . 1(25%)
Perioperative headache or pain near the device . 1(M0) . . 1(25%)
Paresthesia . . 1(M5) . 1(25%)
Spontaneous interruption of stimulation . . . 1(M7) 1(25%)
B. Millet et al.1236frontal lobe, the medial gyrus (BA 10) of the left frontal lobe, and
the anterior cingulate gyrus (BA 32) of the right limbic lobe.4. Discussion
4.1. Summary of evidence
High-frequency DBS proved to be a useful alternative
treatment for our sample of patients diagnosed with stable
TRD. For three of these four patients whose depression had
resisted all previous forms of treatment, the surgical
procedure provided a signiﬁcant improvement in mood, as
attested to by the lower HDRS scores across the 15 months
following the start of stimulation even though no improve-
ment was observed in GAF and social functioning. The
expected improvement occurred later than we had
expected, during the extension phase, when the parameters
could be modiﬁed. Even though the changes were ﬂuctuant
for one patient, compared with the stability observed
during the six-month pre-surgical period, a clear switch of
mood was observed, allowing promoting a modiﬁcation of
parameters used. Due to the very precise targeting per-
formed by each of the four neurosurgeons, and conﬁrmed by
the atlas-based method developed by the Parsi group, all
four patients had very similar electrode implantations.
Our comparison of the outcomes of Acb versus caudate
stimulation suggested that there was a better response to
the former. These results, when added to the ﬁndings
reported by Bewernick et al. (2010),(2012), support the
usefulness of the Acb target. Our target was deeper and
more forward than the one used by these authors, but our
results did not allow us to consider some coordinates more
accurate than another, making it difﬁcult to compare their
efﬁcacy results with ours. However, it would seem relevant
to stimulate Acb's shell, which is more closely related to the
limbic system (Sturm et al., 2003), than its core, in order to
interact with the neuroanatomical structures known to be
implicated in the pathophysiology of depression.
We did not observe any of the frequent side effects
during either the surgical procedure or the postoperative
period, although one patient did attempt suicide during the
15-month follow-up. Regarding eating behavior, three of thepatients presented distinct proﬁles, for while eating beha-
viors remained unchanged for one of them, the opposite
tendency was observed for the other two, regarding com-
pulsive food consumption. From a qualitative point of view,
15 months after the operation, all four patients sounded
better and none complained about the implanted device.
Tolerance (including neuropsychological testing, eating and
sexuality behaviors) was acceptable.4.2. Limitations
Concerning internal validity, like other longitudinal studies
of DBS in TRD, this study was not randomized and did not
allow us to control for spontaneous improvements or a
placebo effect. Placebo responses are indeed frequent in
MDD, and raise many important methodological issues
(Walsh et al., 2002). Moreover, a crossover design would
have been more useful for comparing Acb with the caudate.
Despite this limitation, given our results (no change
observed during the stimulation of the caudate), it would
be hard to justify selecting this target for further explora-
tions. In addition, concerning the Acb target, the greatest
improvements were seen at the highest voltages – voltages
that were not used for the caudate target. Despite these
limitations, given our results at the 9-month follow-up (no
change observed during the stimulation of the caudate), it
is nevertheless difﬁcult to retain this target for further
explorations. Finally, as the caudate stimulation was depen-
dent upon the results of the Acb stimulation, we did not
perform a PET scan after the caudate stimulation, which
might have yielded some interesting results.
Concerning external validity, we found it extremely
difﬁcult to recruit patients suffering from pure TRD.
Patients who meet the criteria for pure TRD are actually
quite rare. In practice, TRD tends to be associated with
comorbid disorders such as alcohol dependence, or else is a
component of a hidden bipolar disorder (Li et al., 2012),
which was revealed here by very careful screening.
In addition, many of the patients who had initially been
recruited as potential candidates for high-frequency DBS
turned out to be responders to one of the treatments
available for TRD. In particular, many of the patients
1237Limbic vs cognitive target for DBS in TRDinitially classiﬁed as resistant according to Thase and Rush
Stage III responded to irreversible MAOI.
To overcome these limitations, we plan to start a
randomized, double-blind, controlled trial (RCT). We will
retain the Acb target and drop the caudate one. To cope
with the recruitment difﬁculties encountered in the present
preliminary study, the STHYM team will consider broader
inclusion criteria, especially in relation to patients suffering
from bipolar depression, as previous studies have suggested
that these patients could also beneﬁt from DBS
(Holtzheimer et al., 2012).5. Conclusion
In conclusion, this preliminary study suggests that Acb,
rather than the caudate, should be retained as a potential
therapeutic alternative neuroanatomic target for patients
suffering from TRD. During the follow-up, 3 out of 4 exhib-
ited stable improvement. Our results highlight the involve-
ment of Acb as a key structure within the cortico-striatal
loop in the pathophysiology of TRD.
The time has come to assess the efﬁcacy of this surgical
procedure using an RCT, in order to see whether this new
technique does indeed represent a fresh source of hope for
patients who have been suffering from severe depression for
many years.Role of funding source
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